This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-EDB scFv to TNFα. It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the EDB as well as the biological activity of TNFα. The fusion protein displays a potent antitumor activity in several immunocompetent murine models of cancer but do not lead to complete remissions of established aggressive tumors. The observed toxicity profile was mild and reversible when intravenously administered to patients with advanced progressive solid tumors in an outpatient setting. This immunocytokine was designed for treating Advanced solid tumors, Advanced pancreatic cancer, Metastatic melanoma.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-193 | Anti-Human Fibronectin Extra Domain-B Recombinant Antibody (Radretumab) | IF, IP, Neut, FuncS, ELISA, FC, ICC | [(scFv - heavy - kappa) - IGHE - CH4]2 |
TAB-001CQ | Anti-Human FN1 Recombinant Antibody (MOR03255) | ELISA, Block, IHC | Human antibody |
TAB-002CQ | Anti-Human FN1 Recombinant Antibody (ME-4C) | ELISA, IHC | Human antibody |
TAB-003CQ | Anti-Human FN1 Recombinant Antibody (1C5) | ELISA, WB | Human antibody |
TAB-071WM | Anti-Human FN1 Recombinant Antibody (CGS-1) | ELISA, WB | Human Antibody |
There are currently no Customer reviews or questions for ACFP-SH092. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.